Brief: Kronos Bio Announces Positive End-Of-Phase 2 Meeting With FDA For Entospletinib In Newly Diagnosed Npm1-Mutated Acute Myeloid Leukemia

Kronos Bio

04/03/2021 12:12

March 4 (Reuters) - Kronos Bio Inc  KRON.O :
    * KRONOS BIO ANNOUNCES POSITIVE END-OF-PHASE 2 MEETING WITH
FDA
FOR ENTOSPLETINIB IN NEWLY DIAGNOSED NPM1-MUTATED ACUTE MYELOID
LEUKEMIA (AML)
    * KRONOS BIO - TO PROCEED WITH PLAN TO ASSESS MEASURABLE
RESIDUAL
DISEASE NEGATIVE COMPLETE RESPONSE AS PRIMARY ENDPOINT IN
REGISTRATIONAL PHASE 3 TRIAL
    * KRONOS BIO INC - PLANS TO INITIATE PHASE 3 TRIAL IN
MID-2021,
WITH MRD NEGATIVE CR DATA EXPECTED IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNXbzsf0y 
Further company coverage:  KRON.O 

 ((Reuters.Briefs@thomsonreuters.com;))